Integrating Genetic Alterations and the Hippo Pathway in Head and Neck Squamous Cell Carcinoma for Future Precision Medicine

Genetic alterations and dysregulation of signaling pathways are indispensable for the initiation and progression of cancer. Understanding the genetic, molecular, and signaling diversities in cancer patients has driven a dynamic change in cancer therapy. Patients can select a suitable molecularly tar...

Full description

Saved in:
Bibliographic Details
Published in:Journal of personalized medicine 2022-09, Vol.12 (10), p.1544
Main Authors: Ando, Toshinori, Okamoto, Kento, Shintani, Tomoaki, Yanamoto, Souichi, Miyauchi, Mutsumi, Gutkind, J. Silvio, Kajiya, Mikihito
Format: Article
Language:English
Subjects:
Breast cancer
Cell proliferation
Gene amplification
Genetic diversity
Growth factors
Head and neck carcinoma
Human papillomavirus
Immune checkpoint inhibitors
Kinases
Localization
Mammals
Mutation
Neck
Phosphatase
Precision medicine
Prostate cancer
Proteins
Review
Signal transduction
Squamous cell carcinoma
Stem cells
Yes-associated protein
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Genetic alterations and dysregulation of signaling pathways are indispensable for the initiation and progression of cancer. Understanding the genetic, molecular, and signaling diversities in cancer patients has driven a dynamic change in cancer therapy. Patients can select a suitable molecularly targeted therapy or immune checkpoint inhibitor based on the driver gene alterations determined by sequencing of cancer tissue. This “precision medicine” approach requires detailed elucidation of the mechanisms connecting genetic alterations of driver genes and aberrant downstream signaling pathways. The regulatory mechanisms of the Hippo pathway and Yes-associated protein/transcriptional co-activator with PDZ binding motif (YAP/TAZ) that have central roles in cancer cell proliferation are not fully understood, reflecting their recent discovery. Nevertheless, emerging evidence has shown that various genetic alterations dysregulate the Hippo pathway and hyperactivate YAP/TAZ in cancers, including head and neck squamous cell carcinoma (HNSCC). Here, we summarize the latest evidence linking genetic alterations and the Hippo pathway in HNSCC, with the aim of contributing to the continued development of precision medicine.
ISSN:2075-4426
2075-4426
DOI:10.3390/jpm12101544